Dr. Scott’s research focuses on viral hepatitis, diseases which have dramatic implications for the health of Americans. Hepatitis C affects nearly 4 million Americans and 170 million worldwide. It is responsible for the doubling of liver cancer in the last decade and is the primary indication for liver transplantation. Hepatitis B is a vaccine-preventable infection afflicting 1 million in the US and 400 million in the world. Fortunately, therapy for hepatitis C is improving rapidly; Dr. Scott has an active research program with novel antivirals, in partnership with pharmaceutical companies.
Using mathematical models, Dr. Scott studied the viral kinetics of hepatitis C on therapy and has modeled the impact of screening all Americans born between 1945-1964. He has partnered with several regional biotechnology companies for the development of novel screening assays for viral hepatitis. In 2009, he launched Project ECHO in Washington State. This innovative telehealth program helps clinicians serving in rural and underserved areas with the evaluation and treatment of hepatitis C. Project ECHO has expanded to include teleconferences in chronic pain, psychiatry, addictions and HIV/AIDS.
Scott JD, Holte S, Urban T, Burgess C, Coppel E, Wang C, Corey L, McHutchison J, Goldstein D. IL28B genotype effects during early treatment with peginterferon and ribavirin in difficult to treat hepatitis C virus infection. J Infect Dis. 2011; 204: 419-25.
• PubMed Abstract